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Multiple environmental triggers have been proposed to explain the increased incidence
of type 1 diabetes (T1D). These include viral infections, microbiome disturbances,
metabolic disorders, and vitamin D deficiency. Here, we used ELISA to examine blood
plasma from juvenile T1D subjects and age-matched controls for the abundance of
several circulating factors relevant to these hypotheses. We screened plasma for sCD14,
mannose binding lectin (MBL), lipopolysaccharide binding protein (LBP), c-reactive
protein (CRP), fatty acid binding protein 2 (FABP2), human growth hormone, leptin, total
adiponectin, high molecular weight (HMW) adiponectin, total IgG, total IgA, total IgM,
endotoxin core antibodies (EndoCAbs), 25(OH) vitamin D, vitamin D binding protein,
IL-7, IL-10, IFN-γ, TNF-α, IL-17A, IL-18, and IL-18BPa. Subjects also were tested
for prevalence of antibodies targeting adenovirus, parainfluenza 1/2/3, Coxsackievirus,
cytomegalovirus, Epstein-Barr virus viral capsid antigen (EBV VCA), herpes simplex virus
1, and Saccharomyces cerevisiae. Finally, all subjects were screened for presence and
abundance of autoantibodies targeting islet cell cytoplasmic proteins (ICA), glutamate
decarboxylase 2 (GAD65), zinc transporter 8 (ZNT8), insulinoma antigen 2 (IA-2), tissue
transglutaminase, and thyroid peroxidase, while β cell function was gauged by measuring
c-peptide levels. We observed few differences between control and T1D subjects. Of
these, we found elevated sCD14, IL-18BPa, and FABP2, and reduced total IgM. Female
T1D subjects were notably elevated in CRP levels compared to control, while males
were similar. T1D subjects also had significantly lower prevalence of EBV VCA antibodies
compared to control. Lastly, we observed that c-peptide levels were significantly
correlated with leptin levels among controls, but this relationship was not significant
among T1D subjects. Alternatively, adiponectin levels were significantly correlated
with c-peptide levels among T1D subjects, while controls showed no relationship
between these two factors. Among T1D subjects, the highest c-peptide levels were
associated with the lowest adiponectin levels, an indication of insulin resistance.
In total, from our examination we found limited data that strongly support
Harms et al. Confirmation and Identification of Biomarkers
any of the hypotheses investigated. Rather, we observed an indication of unexplained
monocyte/macrophage activation in T1D subjects judging from elevated levels of sCD14
and IL-18BPa. These observations were partnered with unique associations between
adipokines and c-peptide levels among T1D subjects.
Keywords: Type 1 diabetes (T1D), acute phase proteins (APP), Vitamin D, virus, cytokine, EndoCAbs, adipokines,
human blood plasma
INTRODUCTION
The clinical definition of type 1 diabetes is not overly
controversial. The absence of insulin production and presence
of circulating antibodies targeting islet cell-associated proteins
(i.e., islet autoantibodies) are sufficient to outline the disease.
However, the mechanism(s) whereby beta cells are ultimately
destroyed remains unclear and highly contested. Leaving aside
known genetic risk associations (1), there remains an abundant
number of hypotheses as to what triggers drive pathogenesis. The
range of suspected triggers is diverse, including viral infection
(2), microbiome disturbances and related gut “leakiness” (3,
4), metabolic disorder (5), vitamin D deficiency (6), and
dysregulated immunity (7, 8). Adding to this broad range is the
high likelihood that these factors can easily interact with one
another, playing upon known genetic predisposal to produce an
exceedingly complex etiology.
In the face of such an extensive array of probable causality,
one enticing option is to investigate each hypothesis. This
approach would avoid a bias of favoritism while the issue remains
contested, and would allow for the observation of multifactorial
causation, if apparent. In pursuing this approach, one is first
confronted with two related concerns: method and scope. While
pancreas and intestinal biopsies would be most appropriate for
these studies, access to these tissues is highly limited, and their
acquisition outside of the postmortem condition can come with
some risk (9). Alternatively, peripheral blood offers a low risk and
more readily available tissue that can be separated into cellular
and plasma components for study. Containing a rich assemblage
of soluble factors, peripheral blood plasma provides an intricate
mosaic of internal health, capable of revealing the turbulent
and heterogeneous immunological landscape to the investigator.
To assess this terrain, multiplex assays and mass spectrometry
have been used in the investigation of T1D previously (10,
11). While these methods can be suitable depending on the
question, they are not appropriate or available for all targets (e.g.,
antibodies targeting viral or islet proteins) and require specialized
instrumentation for analysis. For another option, enzyme
linked immunosorbent assay (ELISA) is a well-established and
reliable alternative in analyte analysis. Although more labor
intensive since only one analyte can be measured at once, it is
methodologically robust. Furthermore, since plate readers are
commonly available, results can be independently confirmed at
laboratories worldwide without unreasonable investments.
With respect to the concern of scope, a vast number of
potential targets in the plasma could be considered relevant to
address these questions. Here, with few exceptions, we directed
our analysis to selected targets that had been investigated
previously and deemed relevant in T1D and/or autoimmunity.
These are described more fully below. By querying several causal
hypotheses, our goal was to work toward a more thorough
evaluation of immunity among diagnosed T1D subjects to
establish potential inroads in therapy and solidify purported
avenues of pathogenesis. Ultimately, the majority of the factors
we measured were similarly abundant in T1D subjects and
controls, yet we did observe a handful of novel differences.
These included increased abundance of sCD14 and IL-18BPa and
unique associations between adipokines and c-peptide among
T1D subjects. Albeit in instances provocative, and certainly with
limitations, our findings did not strongly support any of the
tested hypotheses; rather, they provided hints and suggestions for
future queries.
METHODS
Study Background and Consent
We are performing a collaborative study with researchers
and clinicians at Children’s Hospital and the University of
Nebraska Medical Center designed to explore how genetic and
environmental variables influence the development of type 1
diabetes.We actively recruited diagnosed type 1 diabetic juveniles
and control (no history or family history of autoimmunity,
short stature diagnosis) juveniles from the Endocrine Clinic at
Children’s Hospital. The study was performed under ethical
standards defined by the UNMC Institutional Review Board
(IRB# 107-09-EP) and in accordance with the 1964 Declaration
of Helsinki. All subjects who participated provided informed
consent/assent. Subject characteristics are provided in Table 1.
Sample Processing
We acquired 20mL of venous blood in K2 EDTA vacutainers
(Becton, Dickinson, and Company). Blood samples were
processed within 2 h of blood draw. For plasma isolation, whole
blood tubes were centrifuged at 400 × g for 20min at 18◦C.
Platelet-rich plasma was removed and centrifuged for 10,000× g
for 10min at 4◦C. Supernatents were then pooled and individual
aliquots were flash frozen with dry ice, then stored at −80◦C.
To avoid multiple freeze-thaw cycles, aliquots were thawed and
subdivided into assay-specific volumes, and then refrozen as
described above.
ELISA
The following ELISAs were used according to manufacturers’
recommendations: from R & D systems sCD14 (DC140), MBL
(DMBL00), CRP (DCRP00), Vitamin D BP (DVDBP0), FABP2
(DFBP20), total adiponectin (DRP300), HMW adiponectin
(DHWAD0), leptin (DLP00), high sensitivity IL-7 (HS750),
and IL-18BPa (DBP180); from Enzo BioChem human growth
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TABLE 1 | Patient data.
Control T1D p-value
n (n female) 27 (18) 36 (18)
Age
Mean 9.81 9.47 0.248
Range 8–11 8–11
HbA1c
Mean n/a 8.81 n/a
Range n/a 6.1 - 15.1
BMI
Mean 17.5 20.1 0.012
Range 13.4–30.4 13.7–31.6
Months since diagnosis
Mean n/a 21.8 n/a
Range n/a 0–88
Race/Ethnicity
American Indian 0 1
Asian 2 0




hormone (HGH, KIT148-0001) and 25(OH)Vitamin D (ADI-
900-215); from Hycult Biotech lipopolysaccharide binding
protein (LBP, HK315) and EndoCAb IgM, IgA, and IgG
(HK504-IGG, -IGA, -IGM); from eBiosience/ThermoFisher
total IgA (88–50600), total IgG IgG(88–50550), total IgM (88–
50620), IL-18 (BMS267), high sensitivity IL-17A (BMS2017HS),
high sensitivity TNF-α (BMS223HS), high sensitivity IL-
10(BMS215HS), and high sensitivity IFN-γ (BMS228HS);
from AbCam MDC (ab223866); from Eagle Biosciences
GAD65(GAD31-K01), ICA (ICA31-K01), ZnT8 (ZT831-
K01), IA-2 (IA231-K01), tTG IgA (HTG31-K01), and TPO
(TPO31-K01); from Generic Assays ASCA (4006); from IBL
America parainfluenza 1/2/3 IgG (IB79269), adenovirus IgG
(IB79202), EBV VCA IgG (RE57351), CMV IgG (EG 101),
HSV1 IgG (IB79242), Coxsackievirus IgG (IB05040), echovirus
IgG (IB05049); from Alpco C-peptide (80-CPTHU-E01.1) for
random, non-fasting measurement (12). Absorbance values
were measured using a Biotek H2 Hybrid plate reader (BioTek).
Standard curves were modeled using Gen5 software v 3.05.11
(BioTek). Sample values below the limit of detection (LOD)
were given a synthetic value equaling the LOD/
√
2. For IFN-γ, 1
control and 3 T1Ds were <LOD; for TNF-α, all subjects tested
were <LOD; for IL-17A, 26 controls and 32 T1Ds were <LOD.
Statistics
For pairwise comparisons, sample values were normalized using
natural log transformations and then tested for significant
differences using the two-tailed Student’s t-test. Correlations
were explored using Pearson’s product moment correlation test
on normalized values. Months since diagnosis values, which
contained true zeroes, were normalized using square root
transformations for these tests. For comparisons of pathogen
prevalence, Fisher’s exact test was used. In all cases, a result was
considered significant if p < 0.05. When present, exploratory
sex stratification is intended to help address the issue of
how sex influences health and disease (13, 14). Statistical
tests were performed using SPSS v 25 (IBM) and Prism v
6.03 (Graphpad). Figures were constructed using Prism. Non-
transformed values were depicted for pairwise comparisons to
facilitate interpretation. Descriptive statistics for analyte values
are provided in Supplementary Data 1.
RESULTS
Elevated Autoantibodies and Decreased
C-Peptide Among T1D Subjects
The presence of circulating autoantibodies targeting islet-
associated antigens and an absence of insulin are hallmarks
of T1D. We compared our control and T1D subjects for
presence and abundance of islet cell antibodies (ICA), glutamate
decarboxylase 2 (GAD65), zinc transporter 8 (ZnT8), and
insulinoma antigen 2 (IA-2, or receptor-type tyrosine-protein
phosphatase-like N). The results are presented in Figure 1 and
qualitatively summarized in Table 2. As expected, clinically-
diagnosed T1D subjects were significantly increased for all islet-
associated autoantibodies compared to control (Figures 1A–D).
Interestingly, autoantibodies were also detected among controls
with 5 of 27 having GAD65, 1 of 27 with ZnT8, and 1 of 27 with
IA-2. No control subjects were positive for ICA.
Anti-thyroid peroxidase (TPO)antibodies have been reported
to be elevated in T1D and could indicate or prognose thyroid
autoimmunity (15, 16). We detected TPO autoantibodies in only
4 of 36 T1D subjects and in no controls (Figure 1E, Table 2).
Tissue transglutaminase (tTG) IgA antibodies are associated with
celiac disease, and are not uncommonly detected in juvenile T1D
subjects (17). We detected tTG IgA autoantibodies in 1 control
and 3 T1D subjects (Figure 1F, Table 2). Importantly, tTG levels
are negatively associated with gluten-free diets. As we do not
know our subjects dietary regimen, we may be underestimating
the ability of our subjects to produce these antibodies. Finally,
we observed significantly and drastically reduced random, non-
fasting c-peptide levels among T1D subjects compared to
controls (Figure 1G). Intriguingly, a handful of T1D subjects had
c-peptide levels which were similar to control subjects. These are
explored further below.
Viral Immunoglobulins
Exposure to viruses and other pathogens frequently elicits a
humoral response which is detectable by measuring antigen-
specific immunoglobulins in plasma. This lasting response is
a fundamental component of successful adaptive immunity.
This measurement can provide a murky “history” of previous
viral infection, and virus exposure has been hypothesized
as a causal factor in T1D development. We examined
T1D and control plasma for levels of IgG specific for
adenovirus, parainfluenza 1/2/3, Epstein-Barr virus viral capsid
antigen (EBV VCA), cytomegalovirus (CMV), Coxsackievirus,
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FIGURE 1 | Autoantibody and c-peptide levels among diagnosed T1D subjects and controls. (A–D) Abundance of islet cell antibodies (ICA), glutamate decarboxylase
2 (GAD65), insulinoma antigen 2 (IA-2), and zinc transporter 8 (ZnT8), were all significantly elevated among T1D subjects, consistent with the disease classification.
(E,F) We observed no significant difference in abundance of antibodies targeting thyroperoxidase (TPO) and tissue transglutaminase (tTG), both of which have been
previously associated with type 1 diabetes. (G) Random, non-fasting c-peptide levels were significantly decreased among T1D subjects compared to controls. Bars
represent median values and BI signifies binding index. Dotted lines on autoantibody graphs represent cutoff points for designating positive or negative status.
echovirus, herpes simplex virus 1 (HSV1), and IgA to
Saccharomyces cerevisiae. The qualitative results from these
analyses are presented in Table 3. Antibodies targeting the
common respiratory viruses adenovirus and parainfluenza 1/2/3
were detected in nearly all T1D and control subjects. Prevalence
of Coxsackievirus IgG positive individuals was relatively similar
between controls and T1D subjects. Coxsackievirus IgG was
detected in 9 of 27 (33.3%) controls and 10 of 36 (27.8%) T1D
subjects. Highly similar results were obtained for IgG targeting
echovirus (Supplemental Data 2), another member of the genus
Enterovirus. Ignoring disease classification, female prevalence of
Coxsackievirus IgG was significantly higher (p < 0.0001) with
18/36 (50%) females possessing detectable Coxsackiesvirus IgG,
and only 1/27 (3.70%) in males. Among the herpes viruses, EBV
VCA IgG prevalence was significantly lower among T1D subjects
compared to controls (p = 0.0409), with EBV VCA IgG detected
in 20 of 27 (74.1%) of controls and 17 of 36 (47.2%) with T1D.
CMV IgG prevalence was also lower in T1D, yet this was not
significant (p = 0.2507). CMV IgG was detected in 9 of 27
(33.3) controls and 7 of 36 T1D subjects (19.4%). HSV1 IgG was
detected in 3 of 27 (11.1%) controls and 9 of 36 (25%) with T1D.
Although the prevalence was higher in T1D, this did not reach
significance (p = 0.2069), but approached significance in males
(p = 0.0593). Finally, we were unable to detect S. cerevisiae IgA
(ASCA), a marker associated with some forms of inflammatory
bowel disease (18), in any subjects.
Decrease in Abundance of EndoCAb IgG
With Time Since Diagnosis
Endotoxin core-specific antibodies (EndoCAbs) provide a
sensitive measurement of B cell-driven responses to LPS
with elevations and decreases indicating dynamic exposure to
endotoxin [reviewed in (19)]. Varying EndoCAb levels have
also been associated with autoimmunity (20, 21). We found
no changes in abundance of EndoCAbs IgA, IgG, and IgM
comparing T1D and control (Figures 2A–C). At the same time,
we examined total IgG, IgA, and IgM, whose levels reflect
global immune experience and activation. We observed no
difference between controls and T1D for total IgG and total
IgA levels (Figures 2D,E). However, we found total IgM was
significantly, though modestly, reduced compared to controls.
(Figure 2F). We also observed no difference between controls
and T1D for proportion of EndoCAbs IgG, -A, and -M to total
immunoglobulins G, A, and M (Figures 2G–I). Interestingly,
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Control 0/1/26 (0) 0/0/18 (0) 0/1/8 (0)
T1D 33/2/1 (92) 17/1/0 (94.4) 16/1/1 (88.9)
GAD65
Control 5/0/22 (22.3) 2/0/16 (11.1) 3/0/6 (33.3)
T1D 32/0/4 (88.9) 17/0/1 (94.4) 15/0/3 (83.3)
IA-2
Control 1/1/25 (3.7) 0/1/17 (0) 1/0/8 (11.1)
T1D 22/1/13 (61.1) 10/0/8 (55.6) 12/1/5 (66.7)
ZnT8
Control 1/0/26 (3.7) 1/0/17 (5.6) 0/0/9 (0)
T1D 23/0/13 (63.9) 10/0/8 (55.6) 13/0/5 (72.2)
TPO
Control 0/4/23 (0) 0/1/17 (0) 0/3/6 (0)
T1D 4/1/31 (11.1) 2/1/15 (11.1) 2/0/16 (11.1)
tTG IgA
Control 1/0/26 (3.7) 1/0/17 (5.6) 0/0/9 (0)
T1D 3/0/33 (8.3) 2/0/16 (11.1) 1/0/17 (5.6)
EndoCAb IgG levels as well as the ratio of EndoCAb IgG
to total IgG decreased with months since diagnosis in T1D
(Figures 3A,B). This was not the case for total IgG levels
(Figure 3C), nor for total IgM, IgA, and EndoCAbs IgA and
IgM (data not shown). In total, aside from a modest elevation
of EndoCAb IgG around diagnosis, there is little evidence of
systemic atypical endotoxin exposure in T1D. Furthermore,
previous immunological exposure gauged by circulating IgG
and IgA levels appears comparable between the two groups,
while reduced IgM in T1D may suggest somewhat dampened B
cell activation.
Circulating Levels of sCD14 Are
Significantly Elevated in T1D, While
Elevated CRP Levels Are Specific to T1D
Females
Acute-phase proteins such as lipopolysaccharide binding protein
(LBP), mannose binding lectin (MBL) c-reactive protein (CRP),
and soluble CD14 (sCD14) rapidly change in abundance during
inflammatory responses (22, 23). Fatty acid binding protein 2
(FABP2) is a marker of intestinal epithelial damage and integrity
and can be used as a proxy measure for the health of the
intestinal epithelium (24). We observed significantly increased
sCD14 among T1D subjects, while levels of LBP and MBL were
unchanged between the two groups (Figures 4A–C). CRP levels
were also similar for total T1D and controls, yet upon stratifying
into male and female, we found elevated CRP levels in female
T1D subjects compared to control, while males T1D subjects and
controls were similar (Figure 4D). Finally, we observed slightly
elevated FABP2 levels in T1D subjects (Figure 4E).




Control 27/0/0 (100) 18/0/0 (100) 9/0/0 (100)
T1D 36/0/0 (100) 18/0/0 (100) 18/0/0 (100)
ASCA IgA
Control 0/0/26 (0) 0/0/17 (0) 0/0/9 (0)
T1D 0/0/36 (0) 0/0/18 (0) 0/0/18 (0)
Coxsackievirus IgG
Control 9/2/16 (33.3) 9/1/8 (50)† 0/1/8 (0)†
T1D 10/4/22 (27.8) 9/2/7 (50)† 1/2/15 (5.9)†
CMV IgG
Control 9/0/18 (33.3) 7/0/11 (38.9) 2/0/7 (22.2)
T1D 7/0/29 (19.4) 4/0/14 (22.2) 3/0/15 (16.7)
EBV VCA IgG
Control 20/0/7 (74.1)* 14/0/4 (77.8) 6/0/3 (66.7)
T1D 17/0/19 (47.2)* 9/0/9 (50) 8/0/10 (44.4)
HSV 1 IgG
Control 3/0/24 (11.1) 3/0/15 (16.7) 0/0/9 (0)#
T1D 9/0/27 (25) 2/0/16 (11.1) 7/0/11 (38.9)#
Parainfluenza 1/2/3 IgG
Control 24/2/1 (88.9) 17/0/1 (94.4) 7/2/0 (77.8)
T1D 31/4/1 (86.1) 16/2/0 (88.9) 15/2/1 (83.3)
†
p < 0.0001 when pooling total females (T1D and control) and comparing to total males
(T1D and control).
*p = 0.0409 comparing combined T1D and combined control.
#p = 0.0593 comparing male T1D and male control.
ASCA, anti-Saccharomyces cerevisiae antibodies.
25 (OH) Vitamin D and Vitamin D Binding
Protein Levels Are Similar Among Control
and T1D Subjects
Vitamin D is a powerful immunomodulatory agent involved in
assorted immune pathways and implicated in several diseases
including autoimmunity (25). While multiple factors govern its
abundance and availability, one method by which its circuiting
levels are managed is through the vitamin D binding protein
(BP) (26). Due to the importance of this pathway in immunity,
we sought to investigate vitamin D and vitamin D BP levels
in T1D. We observed no difference in 25(OH) vitamin D and
no difference in vitamin D BP levels among control and T1D
subjects (Figures 5A,B). Furthermore, we observed no difference
in ratio of vitamin D BP to 25(OH) vitamin D among control
and T1D subjects (Figure 5C). This ratio indicates systemic
accessibility to vitaminD. In combination, we found no signs that
vitamin D levels differ between controls and T1D.
Leptin, Adiponectins, and HGH Levels Are
Similar Among Control and T1D Subjects
Energy homeostasis involves cross-talk between multiple tissues
and organ systems. For example, adipokines like leptin and
adiponectin are derived from adipocytes and involved in insulin
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FIGURE 2 | Reduced IgM abundance among T1D subjects, while endotoxin core antibodies (EndoCAb) and total IgG and IgA levels are similar to control.
(A–C) EndoCAb IgG, IgA, and IgM levels were similar among T1D subjects and controls. (D–F) We found that total IgG and total IgA were also similar, while total IgM
was reduced among T1D subjects. (G–I) Finally, the ratio of EndoCAbs to total immunoglobulins were more-or-less equivalent for IgG, IgA, and IgM. Bars represent
median values.
FIGURE 3 | Abundance of EndoCAb IgG decreased with time since diagnosis. (A,B) EndoCAb IgG levels as well as the ratio of EndoCAb IgG to total IgG decrease
with months since diagnosis for T1D subjects. (C) Total IgG levels were not significantly associated with months since diagnosis. Dotted lines represent upper and
lower 95% confidence intervals based on control subjects for each analyte and are included for reference. Data were normalized using natural logarithm (ln) and
square root (sqrt) transformations.
sensitivity and immune modulation (27, 28). Additionally,
human growth hormone (HGH) is secreted from the pituitary
gland and drives growth and energy demand in all tissues
(29). We observed no significant difference in levels of
circulating HGH, total adiponectin, high molecular weight
(HMW) adiponectin, and leptin among control and T1D subjects
(Figures 6A–D). Furthermore, as the ratio of HMW adiponectin
to total adiponectin and to leptin reveal propensities to insulin
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FIGURE 4 | Elevated sCD14 and FABP2 in T1D subjects, and heightened CRP among female T1D subjects. (A) We observed significantly heightened sCD14 levels
among T1D subjects compared to control. (B,C) Lipopolysaccharide binding protein (LBP) and mannose binding lectin (MBL) were relatively similar between the two
groups and revealed no significant differences. (D) C reactive protein (CRP) levels were relatively similar when comparing total T1D subjects, yet when stratifying by
sex, female T1D subjects were significantly elevated in relation to female controls. (E) Fatty acid binding protein 2 (FABP2) levels were significantly elevated in T1D
subjects. Bars represent median values.
FIGURE 5 | 25(OH) vitamin D and vitamin D BP levels are similar between control and T1D subjects. (A,B) We observed no difference in abundance of 25-hydroxy
vitamin D (25(OH) vitamin D) nor vitamin D binding protein (BP) among T1D subjects and control. (C) Additonally, the ratio of vitamin D BP to 25(OH) vitamin D was
similar among the two groups (C). Bars represent median values.
resistance and inflammation (30, 31), we also examined them.
These ratios were unchanged among T1D subjects and controls
(Figures 6E,F).
Elevated Levels of IL-18BP Isoform a
Found in T1D, While Levels of IFN-γ,
TNF-α, IL-10, IL-7, IL-18, IL-17A, and MDC
Are Similar to Controls
Cytokine and chemokines control cellular activation, maturation,
migration and survival, and elevated levels of these can indicate
active infections and inflammatory processes. One difficulty
in the analysis of many circulating cytokines is their relative
scarcity in plasma. We sought to overcome this by utilizing
high-sensitivity assays which are capable of detecting analytes
to the low femtogram per mL level. We analyzed plasma for
circulating levels of IFN-γ, TNF-α, IL-10, IL-17A, and IL-7
using high sensitivity assays. We observed no differences in
levels of circulating IL-7, IL-10, and IFN-γ among controls and
T1D (Figures 7A–C). For TNF-α, we were unable to detect
any quantity in circulation from either our controls or T1D
cohort (Figure 7D). Similarly, IL-17A was mostly undetectable
in the plasma, with only 1 control and 4 T1D subjects
having detectable levels (Figure 7E). Among the more abundant
circulating targets are macrophage derived chemokine (MDC)
as well as IL-18 and its inhibitor, IL-18BPa. These could be
detected using standard ELISA approaches. Neither MDC nor
IL-18 levels were different among T1D and control subjects
(Figures 7F,G). However, IL-18BPa levels were elevated in T1D
compared to controls yet the ratio of IL-18BPa to IL-18 among
T1D and controls was similar (Figures 7H,I). In total, we
found no sign of elevated cytokine in T1D subjects, thereby
providing no evidence of disease-specific immune responses
in progress.
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FIGURE 6 | No difference in levels of adipokines and HGH when comparing control and T1D subjects. (A) We found no difference in abundance of human growth
hormone (HGH) among T1D subjects and controls. (B–D) Similarly, the levels of total adiponectin, high molecular weight (HMW) adiponectin, and leptin were relatively
equivalent when comparing the two groups. (E,F) Finally, the ratios of HMW adiponectin to leptin and HMW adiponectin to total adiponectin were roughly equivalent
among the groups. Bars represent median.
Higher C—Peptide Levels Early After
Diagnosis Are Associated With Lower
Levels of Adiponectin
C-peptide levels offer a direct connection to beta cell function.
Although extremely low in the majority of cases, all of
our T1D subjects had measurable c-peptide. To explore
c-peptide dynamic/beta cell function more fully, first we
compared c-peptide levels with time since diagnosis. Using
untransformed data, we found what appeared to be a rapid
decrease in c-peptide levels with months since diagnosis
appearing as an exponential decay (Supplemental Data 3).
Transforming the data for parametric statistical analysis revealed
a significant decrease in c-peptide levels with time since diagnosis
(Figure 8A). This pattern has been demonstrated previously (32).
We then compared the values from metabolic factors
and autoantibodies with c-peptide levels for correlative
strength. We observed no significant correlations between
autoantibody and c-peptide levels (data not shown). We did
find significant correlations with c-peptide levels among the
adipokines, however. Namely, c-peptide was strongly and
Frontiers in Immunology | www.frontiersin.org 8 September 2020 | Volume 11 | Article 1922
Harms et al. Confirmation and Identification of Biomarkers
FIGURE 7 | Elevated IL-18BPa among T1D subjects, while other cytokines show similar abundance. (A–C) We observed that IL-7, IL-10, and IFN-γ levels were
more-or-less similar among T1D subjects and controls. (D,E). We were unable to detect TNF α and IL-17A in the majority of our subjects. (F) The chemokine
macrophage derived chemokine (MDC) was similarly abundant among T1D subjects and controls. (G,H) While IL-18 levels were roughly equivalent between the two
groups, elevated IL-18BPa levels were observed among the T1D group in relation to control. (I) Although IL-18BPa was elevated, the ratio of IL-18BPa to IL-18 was
similar among T1D subjects and controls. Bars represent median.
significantly associated with leptin levels among controls, yet
the association was relatively weak among T1D subjects and
did not reach significance (Figure 8B). Alternatively, levels of
HMW adiponectin were negatively associated with c peptide
levels among T1D subjects, reaching a significance of p = 0.0145
(Figure 8C). This was in opposition to the control group, in
which c-peptide and HMW adiponectin levels appeared to
possess no association (r = −0.0208, p = 0.918; Figure 8C).
Lastly, we were curious how adipokine levels may change
with time since diagnosis, due to their association with c-
peptide levels. While we noticed no significant association
with leptin levels and months since diagnosis (Figure 8D), we
did observe the both total adiponectin (data not shown) and
HMW adiponectin appeared to increase with months since
diagnosis (Figure 8E). Finally, the association between months
since diagnosis and the ratio of HMW adiponectin to leptin was
relatively weak and not significant (Figure 8F).
DISCUSSION
Cytokines
One general takeaway from our results is an overall lack
of demonstrably unique cytokine responses among diabetics
compared to controls. Among previous studies, our findings are
in agreement with some reports, but not others. For example,
TNF-α has been found to be elevated (33–35), unchanged
(36–39), as well as decreased (40) in type 1 diabetes. Here,
using a high-sensitivity assay with a limit of detection of 130
fg/mL, we were unable to detect circulating TNF-α in any
of our subjects. Similarly, IL-17A was mostly undetectable in
plasma. Indeed, using an assay with a sensitivity of 10 fg/mL
only 1 control and 4 T1D subjects possessed measurable IL-
17A levels. As with TNF-α, IL-17A has been found to be
both elevated (40–42) and unchanged among T1D subjects
(36, 43).
Unlike TNF-α and IL-17A, we were able to observe
measureable MDC, IL-7, IL-10, IL-18, and IFN-γ in the majority,
if not all, of our subjects. Nevertheless, when comparing controls
and T1D, the levels of these cytokines and chemokine were
relatively similar. Unchanged IL-7 levels have been reported by
Alnek and associates (36), while unchanged IL-10 and IFN-γ
levels have been reported by others (39, 44). Contrasting these
findings are reports of reduced (40) or elevated (33, 36, 45)
IL-10 among T1D subjects, as well as elevated IFN-γ (33).
While we observed no difference in IL-18 levels between our
cohorts, we have previously observed a modest IL-18 elevation
in T1D associated with hyperglycemia (46). Elevations in IL-
18 in T1D have also been reported by others (47–49). In
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FIGURE 8 | Unique associations with c-peptide and adipokines among T1D subjects and increasing HMW adiponectin with time since diagnosis. (A) C-peptide levels
rapidly decrease with months since diagnosis. (B) Leptin levels were positively and significantly associated with c-peptide levels in controls, while the relationship was
weaker among T1D subjects and did not reach significance. (C) HMW adiponectin was not significantly associated with c-peptide levels among controls, while T1D
subjects possessed a negative and significant association between HMW adiponectin and c-peptide. (D) Leptin levels were not significantly associated with time
since diagnosis amount T1D subjects. (E) HMW adiponectin levels increase with time since diagnosis among T1D subjects. The results were similar for total
adiponectin (data not shown). (F) The ratio of HMW adiponectin to leptin was weakly associated with time since diagnosis, but did not reach significance. Data were
normalized using natural logarithm (ln) and square root (sqrt) transformations.
sum, circulating cytokine abundance in type 1 diabetes remains
unresolved being awash in conflicting reports. Such widely
variable results could represent a bevy of type I and/or type II
errors due to sampling bias, flaws in experimental design, and/or
technical differences. For example, among the studies cited for
the analysis of TNF-α and including ours, no group used the same
methodology. For subject characteristics, six of the cited TNF-
α studies focused on juveniles, while two investigated a broader
age range. These and other aspects of experimental design may
explain these disparate conclusions. Additional variables are that
glycemic excursions and ketoacidosis can impact abundance
of several circulating cytokines (50–52). Lastly, the episodes
that could create detectable cytokine differences may only
occur well-before diagnosis, during discrete and brief windows
of time.
Although not a cytokine per se, we observed elevated IL-
18BPa among T1D subjects and this elevation appeared most
prominent in females. IL-18BP is a natural inhibitor of IL-
18 function (53). We previously examined IL-18BP using
a commercially available assay which did not differentiate
isoforms (46). Using that previous approach, we observed similar
concentrations between diabetics and controls. Interestingly,
although IL-18BPa was elevated in our current cohort, the
proportion of IL-18BPa to IL-18 was similar among controls
and diabetics. This is consistent with other reports which
demonstrate IL-18BP and IL-18 increasing and decreasing
concordantly (54, 55), except in unique pathologies (56). While
a provocative finding, the elevation of IL-18BPa raises the
questions of source and cause. To that end, we found no
correlative association with IFN-γ levels (data not shown),
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which could be expected if a feedback loop was observable in
circulation (57).
Vitamin D
Reduced vitamin D levels have been hypothesized as a risk
factor for the development of type 1 diabetes and other forms of
autoimmunity [reviewed in (58)]. These reductions are posited
to have a negative effect on both innate and adaptive immunity
(ibid.). Here, we report no significant differences among T1D
subjects and controls for vitamin D BP and 25(OH) vitamin
D levels, as well as for the ratio of vitamin D BP to 25 (OH)
vitamin D, an estimate vitamin D accessibility. Our results stand
in contrast to previous reports of reduced vitamin D binding
protein in type 1 diabetes (59), and contribute to the unsettled
issue of 25(OH) vitamin D levels among type 1 diabetics as
either reduced (60, 61) or unchanged (62). Finally, many of our
T1D subjects and controls could be described as deficient for
vitamin D, in line with previously published results (63). We
are wary of assigning this designation for two reasons. First,
seasonal variation can effect vitamin D levels and our subjects
were sampled through Fall—early Spring sequence of time, when
solar exposure would be limited. Second, there is some indication
that designations of “deficiency” may be over-applied and should
be used more judiciously [see (64)].
Pathogens
Our query of previous exposure to a limited range of
pathogens showed both similarities and differences for relatively
common viruses. Firstly, adenovirus and parainfluenza 1/2/3
responses were generally similar between T1D and control.
Both adenovirus and the parainfluenza group are common
childhood pathogens and would be expected to be highly
seroprevalent. None are known to form chronic infections,
and, to our knowledge, have not been associated with
T1D incidence.
Alternatively, Coxsackievirus has a long history of association
with T1D [reviewed in (65)]. We found Coxsackievirus IgG
prevalence was also similar between groups, demonstrating
equivalent exposure and responses among T1D and controls.
Therefore, we have no evidence to implicate Coxsackievirus
in T1D pathogenesis. One unexpected finding was the
significantly higher prevalence of Coxsackievirus/echovirus
IgG in females rather than males. Sex-based differences in
viral responses are well-documented (66), and this is likely one
such example.
The Coxsackievirus assay we used contains a mixture of
VP1 proteins from Coxsackievirus B1, B3, and B5 (personal
communication from manufacturer). The responses measured
would presumably be limited to those strains. However, we
ran echovirus IgG assays at the same time for comparison and
observed nearly perfect correlation between the two assays. This
echovirus assay utilizes VP1 proteins from echovirus E6 and E9
(personal communication from manufacturer). Our concordant
results between the Coxsackievirus and echovirus assays denotes
broad cross-reactivity among enteroviral VP1. Such VP1 cross-
reactivity has been reported previously (67, 68). From these
results, it’s likely that our Coxsackievirus/echovirus IgG positive
subjects bind VP1 proteins from other members of Enterovirus B,
if not other species in the genus.
In contrast to the other pathogens, herpesviruses are all
capable of forming chronic infections and, thus, have profound
impact on the immune system. Prevalence of EBV andCMVwere
both lower among T1D compared to controls. This reached a
modest level of significance for EBV and was most prominent
among females. Unexpectedly, HSV1 prevalence was higher in
T1D and those positive were exclusively male. The meaning
behind these changes in herpesvirus prevalence is not known,
although they are certainly provocative due to the involvement
of both CMV and EBV in autoimmunity (69, 70). Due to the
tightly-matched age and localized residence of our group, it
would expected that viral exposure and response should be
similar. Whether these reductions reflect compromised immune
responses, unequal exposures, or a random outcome of sampling
is unknown. To resolve this ambiguity, we are planning to test
additional, larger groups for these and other viruses.
Systemic Endotoxin and Acute Phase
Responses
Microbially-based etiologies with associated intestinal
permeability have become relatively popular causal hypotheses
for autoimmunity and type 1 diabetes in general (71). From our
analysis, we found limited supportive data indicating elevated
systemic endotoxin or other microbial factors among T1D
subjects. Importantly, we observed no significant differences in
relative abundance of EndoCAb antibodies using a commercial
assay which measures endotoxin-targeting immunoglobulins
targeting four groups of bacteria (e.g., Escherichia coli, Klebsiella,
Pseudomonas and Salmonella—manufacturer’s communication).
In contrast to our findings, at least one previous report has
shown substantial reductions in EndoCAb IgG levels among
T1D subjects compared to controls (34). Similarly to the
EndoCAbs, we found MBL and LBP levels were not significantly
different between our groups. While more will be said of MBL
below, our findings with LBP are in line with a previous report
showing similar LBP levels among T1D and control (72), while
in opposition to a report showing reduced LBP among T1D
subjects (34). Lastly, we observed no significant difference
between control and T1D subjects for CRP, a protein with anti-
microbial functions denoting generalized inflammation (73).
However, upon stratifying by sex, female T1D subjects appeared
elevated for CRP while male T1D subjects were relatively similar
to control. As already noted, female T1D subjects were also
more prominently elevated for IL-18BPa. Yet, the connection
between CRP and IL-18BPa is unclear in the absence of a causal
intermediary. At this point, we have no evidence to advance or
dismiss a microbial origin for these sex-specific responses.
Regarding MBL, previous reports have shown it to be
increased in T1D, specifically when comparing high-producing
MBL genotypes (74), or when comparing T1D subjects with
at-risk siblings (75). As our study did not involve genetic
recognition of MBL genotypes, nor at-risk siblings, we were
unable to explore these dimensions.We therefore cannot rule out
similar genetically-based differences.
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Circulating FABP2 levels can be used as sign of intestinal
epithelial damage (76, 77), with elevation being suggestive of
increased systemic exposure to gastrointestinal denizens and
their byproducts. Although we observed a significant elevation in
FABP2 among T1D, this was a very modest increase, and, upon
stratification by sex, was mostly associated with males. This could
be interpreted as a sign of minor intestinal epithelial disturbance
among juvenile male type 1 diabetics. However, a much larger
cohort should be examined to pursue this novel finding robustly.
In contrast to these negative or equivocal results, two of
our findings could support the concept that elevated microbial
exposure is associated with T1D. One, we observed significantly
elevated sCD14 levels among T1Ds, contrasting a previously
report of unchanged sCD14 in T1D (34). While sCD14 functions
to direct LPS responses in circulation (78–80), its release is also
a sign of general monocyte activation (81). Thus, elevations
are difficult to causally define. Second, we found elevated
levels of EndoCAb IgG early following diagnosis. This suggests
a heightened humoral response to endotoxin in the events
leading to and immediately following clinical presentation of
disease. As one can only extend a cross-sectional analysis so far,
longitudinal analysis of at-risk subjects is the logical follow-up
from these findings.
Adipokines
Our examination of the adipokines and HGH revealed a relative
equivalence in abundance among control group and T1D.
This is contrary to previous reports showing elevated leptin
and adiponectin (44, 82), as well as HGH (83, 84), in T1D.
Although relative abundance was equivalent, we did observe
unique associations between the adipokines and c-peptide
levels among the T1D group. Both leptin and adiponectin are
thought to influence insulin sensitivity (85, 86). Regarding leptin,
we observed a strong positive correlation between c-peptide
levels and leptin levels in control group, yet the association
was relatively weak in T1D. Furthermore, we observed little
change with leptin levels or its ratio with HMW adiponectin
over time since diagnosis. Thus, in an environment of highly
reduced natural insulin secretion, the fine-tuned relationship
between leptin and insulin may be dysregulated. Alternatively,
HMW adiponectin was negatively correlated with c-peptide
among the T1D group, while control group showed no definite
relationship between the two. Thus, the T1D subjects with
the highest c-peptide had the lowest HMW adiponectin levels.
Since the subjects with high c-peptide were relatively early from
diagnosis, there could be a type of adiponectin-associated insulin
resistance present at diagnosis among some subjects. The idea of
insulin resistance early following diagnosis has been suggested
previously (87), yet a formal mechanism is wanting. Nevertheless,
this does not appear to be a lasting condition as we observed that
adiponectin abundance increased with time since diagnosis.
CONCLUSION
We investigated several prevailing hypotheses into the
pathogenesis of T1D by screening human plasma for the
abundance of multiple pertinent targets. Our study was
not without limitations, however. First, it was confined to
measurements in plasma due to the inaccessibility of the target
tissues. The immune response driving beta cell destruction is
likely subtle, judging from what is known of human insulitis
(88). Thus, it may be that peripheral measurements are incapable
of detecting localized tissue-specific responses. Second, as has
been mentioned, the study was cross-sectional. Longitudinal
analysis of subjects may provide a more telling examination of
such dynamic factors. Third, it could be that the majority of
these responses occur during the prodromal period, and that
following diagnosis, the major pathogenic events are no longer as
easily detectable. Fourth, our T1D group possessed higher mean
BMI than our control group. Our results may be confounded by
this difference. Fifth, being focused on environmental factors,
our analysis did not include an evaluation of HLA class I and
II. Sixth, while we attempted to survey the literature to pick
appropriate targets to test these hypotheses, it may be that we
selected inappropriately and that other soluble factors may
properly reveal such relationships. To that end, we encourage
continued investigation.
With these limitations in mind, we found that among tightly
age-matched juvenile T1D subjects and heathy controls, there are
few measurable differences in abundance of disease-associated
circulating soluble factors. While we observed enticing hints of
potential causality, we found scant strong evidence supporting
any of the causal hypotheses explored. Our inability to observe
strong evidence could be due to its non-existence or could be
due to the limitations described above. To fully unravel the
contribution of the environment to the disease, additional study
of subjects at-risk of developing T1D and soon after diagnosis
is required.
Finally, of the significant differences we observed, sCD14
and IL-18BPa are most statistically robust. Being produced
chiefly by monocytes and macrophage, these elevations suggest
heightened activation of monocytes and monocyte-derived cells.
It remains to be determined if these elevations are associated
with T1D pathogenesis and what specific stimuli are driving
these changes.
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